Intrexon Corp (NASDAQ:XON)’s share price traded up 8.1% on Tuesday after an insider bought additional shares in the company. The stock traded as high as $6.10 and last traded at $6.00. 3,469,849 shares traded hands during trading, an increase of 48% from the average session volume of 2,348,858 shares. The stock had previously closed at $5.55.
Specifically, CEO Randal J. Kirk purchased 1,257,727 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were bought at an average price of $4.40 per share, for a total transaction of $5,533,998.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Randal J. Kirk sold 95,241 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $0.65, for a total value of $61,906.65. The disclosure for this sale can be found here. Insiders purchased a total of 3,402,182 shares of company stock worth $15,739,033 in the last quarter. Company insiders own 48.20% of the company’s stock.
A number of research firms have recently commented on XON. Northland Securities reiterated a “hold” rating and issued a $7.00 price objective on shares of Intrexon in a report on Tuesday, May 14th. JMP Securities reiterated a “buy” rating and issued a $43.00 target price on shares of Intrexon in a report on Wednesday, March 6th. Finally, BidaskClub upgraded Intrexon from a “sell” rating to a “hold” rating in a report on Thursday, May 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. Intrexon has an average rating of “Hold” and an average price target of $28.60.
The company has a current ratio of 3.91, a quick ratio of 3.57 and a debt-to-equity ratio of 0.76. The firm has a market cap of $868.13 million, a PE ratio of -4.38 and a beta of 1.84.
Intrexon (NASDAQ:XON) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.28). Intrexon had a negative net margin of 363.14% and a negative return on equity of 26.52%. The company had revenue of $23.30 million during the quarter, compared to analysts’ expectations of $32.12 million. During the same period in the prior year, the company earned ($0.36) earnings per share. The business’s quarterly revenue was down 41.2% compared to the same quarter last year. On average, equities analysts forecast that Intrexon Corp will post -1.17 EPS for the current fiscal year.
WARNING: This article was originally published by Sundance Herald and is owned by of Sundance Herald. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://sundanceherald.com/2019/06/11/intrexon-nasdaqxon-trading-8-1-higher-after-insider-buying-activity.html.
Intrexon Company Profile (NASDAQ:XON)
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Featured Article: What Are Cryptocurrencies?
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.